Jean Bourhis, MD, discusses results from the phase 2 study of xevinapant plus chemoradiation vs placebo and chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.
Jean Bourhis, MD, a professor of radiation oncology at the University of Paris, discusses results from the phase 2 study of xevinapant plus chemoradiation vs placebo and chemoradiation in patient with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN; NCT02022098).
Results from the 5-year analysis of the study were presented during the European Society of Medical Oncology Congress 2022 by Bourhis. It was shown that the addition of xevinapant to standard-of-care chemoradiation improved the durability of responses in patients with LA SCCHN.
0:08 | The study was a phase 2 randomized trial comparing placebo versus xevinapant with standard of care in patients with locally advanced from cell carcinoma the head and neck. These patients were really high-risk patients, the most advanced among the locally advanced cases. And we knew already that xevinapant was active and well tolerated in the same study. tThe results that we presented [at ESMO] are long-term follow up results. And especially we have data here on overall survival at 5 years, which we didn't have before.
1:03 | What do we see here in this study with long-term follow up the 5-year overall survival is markedly improved with the xevinapant when compared to placebo. And there is nearly a doubling of the overall survival at 5 years. The data [shows that] it's from 28%, with placebo to 53% with xevinapant and we can say that in this selection of patients, again with really high-risk, locally advanced squamous cell cancer of the head and neck. This is something we've never seen in the last 3 decades because the standard of care, cisplatin radiotherapy, has never been improved with the new treatme
Targeted Therapies Continue to Push the Field of EGFRm Lung Cancer Forward
December 6th 2023In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the ever-changing treatment landscape for EGFR-mutated lung cancer, as well as the unmet needs and potential next steps for research in this space.
Read More
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More